Resistance mutation info of drug
Drug General Information | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug ID | D00FGR | ||||||||||
Drug Name | Miltefosine | ||||||||||
Synonyms | HDPC; HePC; Hexadecylphosphocholine; Hexadecylphosphorylcholine; Impavido; Miltefosina; Miltefosinum; Miltex; Baxter Oncology brand of miltefosine; Baxter brand of miltefosine; Miltefosin C; Prasfarma brand of miltefosine; D 18506; IN1227; D-18506; H-1850; M-7200; Miltefosina [INN-Spanish]; Miltefosine (INN); Miltefosine[INN:BAN]; Miltefosinum [INN-Latin]; N-Hexadecylphosphorylcholine; TF-002; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline, hexadecyl hydrogen phosphate, inner salt; Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; 1-Hexadecylphosphorylcholine; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide | ||||||||||
Drug Type | Small molecular drug | ||||||||||
Therapeutic Class | Antifungal Agents | ||||||||||
Company | Aeterna Zentaris | ||||||||||
Structure | |||||||||||
Drug Resistance Mutations | |||||||||||
Target Name | Parasitic Phospholipid-transporting ATPase (LdMT) | Target Info | |||||||||
Gene Name | LdMT | ||||||||||
Uniprot ID | Q6VXY9_LEIDO | ||||||||||
Species | Leishmania donovani | ||||||||||
Reference Sequence |
MPNQPPCWRKCLSTRIFPDKLSKSFCCFSAEADVDEDDEVIVYLNDPELNAQFNYPSNFI RTSKYTLISFLPLSLLLEFKKVSNLYFLMNVIFSLIPGVSPLSPATSIAPLSFVLIVALI KEGVEDIKRHQADNRANSILVQVLRNGKLVSVHSKDIHPGDVMRIKNGEEVRADVVMLAS SVEEGQAFIDTCNLDGETNLKSRKALEATWALCEVEAIMNSTAVLHTSKPDPGLLSWAGL LEINGEEHALSLNQFLYRGCVLRNTDWVWGMVAYAGVDTKLFRNLKPKPPKSSNLDRKLN YFIIAILIFQNIMLFILASMAVWWNSKYRETPYLRFFISFRKNVTLWGYRYLSYFILLSY CVPISLFITIEVCKVVQAQWMRVDCLMMEYMSNRWRHCQPNTSNLNEQLAMVRFIFSDKT GTLTENVMKFKLGDALGNPIDADNLDECIAQLRKEAESKGLGPLQEYFLALALCNTVQPF KDDTDDLGVVYEGSSPDEVALVETAAAVGYRLISRTTKSITLLLHDGTRKVYNILATLEF TPDRKMMSIIVEDSDTKKITLYNKGADSFIRPQLSRAPDVQGHIENVEIPLTEMSSSGLR TLLVCAKDITRRQFDPWFEKFVEAGKSLHNRSSNIDKVCLEMEQDMRLVGATAIEDKLQD EVPETLSFFLSAGVIIWMLTGDKRETAVTIAATSTLCDPRNDFIDHIDIGHLNSSDPKAI ERVGRDLEVVEQHIALKGTHKERRCTLVIDGPALNIAMEHYFDQFLRLSHQVNSAVCCRL TPIQKATVVRMFQKSTGKTALAIGDGANDVSMIREGRVGVGIIGLEGAHAALAADYAIPR FKHLRRLCAVHGRYSLFRNASCILVSFHKNITVSVVQFIFAFYVGFSGLTLFDGWMLTFY NVLLTSIPPFFMGIFDKDLPEDALLERPKLYTPLSHGEYFNLATLLRWFVESLTTAVILF YAAYPTLIRQDGSHQRYTGGETGTLVFSGLILVIQTRFILQIRYWQWLQVFGMAMSIFLF LLLFLVYSAIPSVFSDTNFYYQAFDLMSTAKYWFFLLLYVGTEVVVVLGVMTFQKNLFPT LRDVAERQYAVQNGGKL [Leishmania donovani] |
||||||||||
Targeted Disease | Leishmaniasis | ||||||||||
Drug Resistance Mutations |
|
||||||||||
|
|||||||||||
Target Name | Parasitic Phospholipid-transporting ATPase (Ros3) | Target Info | |||||||||
Gene Name | Ros3 | ||||||||||
Uniprot ID | Q0P0L8_LEIDO | ||||||||||
Species | Leishmania donovani | ||||||||||
Reference Sequence |
MAPLPPKPHSKNRIEQQQLPHIYARHSPLSVSVVFFILAVAAIPIGVLVIVSGDLTTRLD FRYDHINSYKFAMGAAGEFAVNFPFNGTMYSSGVKTRLMFSLHQSLTAPVYMQYRLSPFF QNYRYFTASVDYSQLSGRASAISKLCAPFRFPGEATGDSVSGYYNPCGAYPWAMFNDSIS LYRTDGTLICDGSAFTANGTSLAANNKCVKSGIARPSDVKERYNPPREIPGNGPMWSAGG NKSATDPYLREGYYYKEPGHKIPLSIDEDLIVWLDPAFTSDVTKNYRILNVDLPAGDYYF EITEQYPTAPYASHKFVQLATRSWIGGRSHVLGSLLIIMGGTAFIMAVTLLSVKYLIMPV YTEDI [Leishmania donovani] |
||||||||||
Targeted Disease | Leishmaniasis | ||||||||||
Drug Resistance Mutations |
|
||||||||||
Target Name | Fungal Metacaspase-1 (MCA1) | Target Info | |||||||||
Gene Name | MCA1 | ||||||||||
Uniprot ID | MCA1_YEAST | ||||||||||
Species | Saccharomyces cerevisiae | ||||||||||
Reference Sequence |
MYPGSGRYTYNNAGGNNGYQRPMAPPPNQQYGQQYGQQYEQQYGQQYGQQNDQQFSQQYA PPPGPPPMAYNRPVYPPPQFQQEQAKAQLSNGYNNPNVNASNMYGPPQNMSLPPPQTQTI QGTDQPYQYSQCTGRRKALIIGINYIGSKNQLRGCINDAHNIFNFLTNGYGYSSDDIVIL TDDQNDLVRVPTRANMIRAMQWLVKDAQPNDSLFLHYSGHGGQTEDLDGDEEDGMDDVIY PVDFETQGPIIDDEMHDIMVKPLQQGVRLTALFDSCHSGTVLDLPYTYSTKGIIKEPNIW KDVGQDGLQAAISYATGNRAALIGSLGSIFKTVKGGMGNNVDRERVRQIKFSAADVVMLS GSKDNQTSADAVEDGQNTGAMSHAFIKVMTLQPQQSYLSLLQNMRKELAGKYSQKPQLSS SHPIDVNLQFIM [Saccharomyces cerevisiae] |
||||||||||
Targeted Disease | Leishmaniasis | ||||||||||
Drug Resistance Mutations |
|
||||||||||
References | |||||||||||
REF 1 | CRISPR-Cas9-Mediated Genome Editing in Leishmania donovani. MBio. 2015 Jul 21;6(4):e00861. | ||||||||||
REF 2 | Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India. Parasit Vectors. 2017 Jan 31;10(1):49. | ||||||||||
REF 3 | Functional disruption of yeast metacaspase, Mca1, leads to miltefosine resistance and inability to mediate miltefosine-induced apoptotic effects.Fungal Genet Biol.2014 Jun;67:71-81. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.